semaglutide and bowel obstruction Can a patient who developed a while on a GLP‑1 receptor agonist (e.g., exenatide, liraglutide, semaglutide, dulaglutide) safely continue the GLP‑1 therapy? semaglutide ileus lawsuit in louisiana

Tirzepatide extreme appetite suppression can exacerbate disordered eating patterns and may be psychologically harmful for individuals with active eating disorders

Weight regain risk is highest in the first 3 to 6 months after stopping, with some patients reporting 30-50% of lost weight returning during this window

The evolution of GLP-1 agonists has led to amazing results in weight loss

Astrup A, Carraro R, Harper A, et al

Intervention Seventy eligible participants were randomly assigned (1:1) to either semaglutide 2.4 mg weekly (Novo Nordisk) ( n = 35) or placebo (saline solution) ( n = 35), using self-administered once-weekly subcutaneous injections with identical-appearing pens

The American Medical Association's 2024 policy statement endorsed telehealth as appropriate for obesity pharmacotherapy initiation and management, noting that remote monitoring of weight, blood pressure, and gastrointestinal side effects is feasible and effective 17